Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2002

View Archived Issues

Aventis Pasteur patents multivalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine

Novel prodrugs of antitumor compounds designed by academic researchers

PPAR agonists in the development pipeline at Merck

Modulators of PPARgamma receptors and their use in obesity, diabetes and lipid disorders

Novel MCP-1 antagonists prepared and tested by Telik and Sanwa researchers

Altana's new tryptase inhibitors with potential in asthma and COPD

BG-777 completes phase I

Preliminary phase I results for NicVAX

Greater reduction in bone resorption reported for alendronate vs. risedronate in osteoporosis

Efficacy and safety of KUR-1246 as a new tocolytic agent further explored

LyphoDerm evaluated in phase II trial in hard-to-heal venous leg ulcers

Neutralase phase III protocol submitted

COGNIShunt enters phase III in Alzheimer's disease

First 20 sites open in phase III trial of Xyotax in NSCLC

ICA-17043 receives fast track status in sickle cell anemia

Elite and Elan's joint venture terminated

VRC-4219: a bactericidal protein synthesis inhibitor as a promising new lead antibiotic

Deoxynegamycin and derivatives under evaluation at Versicor as novel antibiotics

Results of collaborative research on 15-methylketolides at J&J and Kosan discussed at ICAAC

More on negamycin-based antibiotics identified at Versicor

E21R continues in development for rheumatoid arthritis

Anxiolytic- and antidepressant-like properties demonstrated for novel CRF1 antagonist

Extensive pharmacological evaluation of S-35966 underlines promise as an antidepressant

Human pharmacokinetics of potential new antiepileptic agent reported in Madrid

GSK researchers design thiazoles for PPAR-mediated diseases

Novel immunomodulating and antiinflammatory agents covered by Sumitomo patent

Major developments related to Inspire's potential CF therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...